This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Venous Thromboembolism (VTE)
  • /
  • Rivaroxaban vs Warfarin and Risk of Post-Thromboti...

Rivaroxaban vs Warfarin and Risk of Post-Thrombotic Syndrome among Patients with Venous Thromboembolism.

Read time: 1 mins
Published:21st Feb 2018
Author: Søgaard M, Nielsen PB, Skjøth F, Kjældgaard JN, Coleman CI, Larsen TB.
Availability: Pay for access, or by subscription
Ref.:Am J Med. 2018. pii: S0002-9343(18)30118-9.
Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism

The effectiveness of rivaroxaban to reduce post-thrombotic syndrome in patients with venous thromboembolism is largely unknown. We compared rates of post-thrombotic syndrome in patients given rivaroxaban versus warfarin in a cohort of routine clinical care patients with incident venous thromboembolism.

Methods: We linked Danish nationwide registries to identify all patients with incident venous thromboembolism who were new users of rivaroxaban or warfarin and compared rates of post-thrombotic syndrome using an inverse probability of treatment weighting approach to account for baseline confounding.

Results: We identified 19,939 oral anticoagulation naive patients with incident venous thromboembolism treated with warfarin or rivaroxaban (mean age 64 years, 48% females, 45.5% with pulmonary embolism). The propensity-weighted rate of post-thrombotic syndrome at 3 years follow-up was 0.53 incidents per 100 person-years with rivaroxaban versus 0.55 per 100 person-years with warfarin, yielding a hazard rate of 0.88 (95% confidence interval 0.66-1.17). This association remained consistent across types of venous thromboembolism (deep venous thrombosis vs. pulmonary embolism, and provoked vs. unprovoked venous thromboembolism), and when censoring patients with recurrent venous thromboembolism.

Conclusions: In this clinical practice setting, rivaroxaban was associated with lower but statistically non-significant rates of post-thrombotic syndrome, which did not appear to be mediated only by an effect on recurrent venous thromboembolism.


Read abstract on library site

Access full article